---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-046085"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:53:33.400077+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Clearside posts Q4 net loss $7.3M; cash to Q4 2025; FDA aligns on CLS-AX Phase 3 in wet AMD

## Summary
- Q4 2024 net loss $7.3M ($0.10/sh) vs $4.8M ($0.08) in Q4 2023; FY loss $34.4M ($0.47) vs $32.5M ($0.53).
- Cash $20.0M at Dec 31, 2024; expected to fund operations into Q4 2025.
- FDA alignment on Phase 3 for CLS-AX in wet AMD: two non-inferiority trials, sham control, after positive Phase 2b.
- Partner Arctic Vision NDA for ARCATUS (XIPERE) in uveitic macular edema accepted in China; also approved in Australia and Singapore.
- Tony Gibney appointed Chair of Board effective November 1, 2024.

## SEC filing metadata
- accession: 0000950170-25-046085
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017025046085/0000950170-25-046085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017025046085/clsd-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-046085
- JSON: https://secwatch.observer/filing/0000950170-25-046085.json
- Plain text: https://secwatch.observer/filing/0000950170-25-046085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.